Abecma (Idecabtagene Vicleucel Dispersion for infusion)

Abecma is indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody.

• Treatment of multiple myeloma that has progressed after standard regimens.
• Use after failure of at least one proteasome inhibitor such as bortezomib or carfilzomib.
• Use after failure of an immunomodulatory drug such as lenalidomide or pomalidomide.
• Use after failure of an anti‑CD38 antibody therapy, for example daratumumab.
• Consideration in patients who are eligible for autologous cell collection and manufacturing.

• Idecabtagene vicleucel is an autologous chimeric antigen receptor (CAR) T‑cell product. Patient T cells are harvested, transduced with a viral vector encoding a CAR that combines an anti‑BCMA single‑chain variable fragment with intracellular signaling domains (CD3ζ and costimulatory motifs). After infusion, the engineered T cells recognize BCMA on malignant plasma cells, become activated, proliferate, and release cytotoxic granules, leading to targeted tumor cell death.

Adverse reactions to Abecma have been reported and are categorized by frequency and severity.

Common

• Cytokine release syndrome (CRS) presenting with fever, hypotension, or hypoxia.
• Fatigue or generalized weakness.
• Nausea, vomiting, or decreased appetite.
• Diarrhea or abdominal discomfort.
• Low blood cell counts (neutropenia, anemia, thrombocytopenia).

Serious

• Neurotoxicity (immune effector cell‑associated neurotoxicity syndrome, ICANS) with confusion or seizures.
• Severe infections, including bacterial, viral, or fungal.
• Tumor lysis syndrome leading to electrolyte abnormalities.
• Prolonged cytopenias requiring transfusion support.
• Secondary malignancies such as therapy‑related myelodysplastic syndrome.

Before initiating Abecma, clinicians should assess several safety considerations and monitor patients closely during and after treatment.

• Evaluate for active infections and treat them prior to cell infusion.
• Perform comprehensive cardiac assessment, as CRS can precipitate cardiac dysfunction.
• Screen for prior or concurrent malignancies that could be affected by immunosuppression.
• Monitor neurologic status regularly to detect early signs of ICANS.
• Assess organ function (hepatic, renal, pulmonary) because severe toxicities may be amplified.
• Ensure adequate venous access for infusion and potential emergency interventions.
• Provide patient education on symptoms that require immediate medical attention.

Abecma may interact with other therapies that affect immune function or cytokine activity, and certain medications should be avoided or used cautiously.

Avoid

• Live or attenuated vaccines administered during the treatment period.
• Concurrent use of other CAR T‑cell products or gene‑editing therapies.
• Strong immunosuppressants that could diminish CAR T‑cell expansion (e.g., high‑dose steroids beyond protocol).

Use with caution

• Concomitant chemotherapy agents that cause myelosuppression.
• Anticoagulants or antiplatelet drugs, given the risk of thrombocytopenia.
• Medications that prolong QT interval, as electrolyte shifts may occur during CRS.